ArticleJournal of optimization theory and applications2026
Optimal Multi-Drug Therapies for Antimicrobial Resistance with Horizontal Transfer.
Article in Journal of optimization theory and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of antimicrobial resistance (AMR) is a global health threat that can be mitigated through the careful planning of multi-drug therapies. We analyse a model that captures the interplay between the host immune system and susceptible and resistant bacterial populations, accounting for the use of antibiotics and for treatment-induced mutations and horizontal transfer phenomena that favour the growth of resistant populations. We extend the model to consider multiple antibiotics and all the ensuing possible combinations of resistance. We formulate an optimal control problem aimed at minimising the overall bacterial population size as well as the use of antibiotics, and we rigorously prove that an optimal solution exists, which can be thus computed numerically. For the considered optimal control problem, we analyse necessary conditions for optimality based on the Pontryagin minimum principle, as well as singular controls. We also discuss an alternative approach for treatment design through a model predictive control (MPC) scheme. Our computational experiments, which illustrate both the direct solution to the optimal control problem and the MPC approach, with realistic parameters from the biological literature and initial conditions chosen according to several different scenarios, validate our theoretical results and demonstrate the flexibility of the framework, which adapts the therapy to the presence and numerosity of resistant populations, so that the optimal treatment strongly depends on both the cost functional weights and the initial conditions for the system dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.